Managing Cardiac Rehabilitation

Structures cardiac rehab prescriptions with exercise parameters and risk stratification.

Why This Skill Exists

Cardiac rehabilitation reduces cardiovascular mortality by 20–30% and all-cause mortality by 13–24%, yet fewer than 25% of eligible patients are referred or enrolled. CMS expanded coverage in 2024 to include heart failure (HFrEF) as a qualifying diagnosis, and the AHA/AACVPR recognize cardiac rehab as a Class I recommendation for post-MI, post-CABG, post-PCI, stable angina, heart failure, and post-valve surgery patients.

The exercise prescription in cardiac rehabilitation must be individualized based on risk stratification, functional capacity, comorbidities, and hemodynamic response to exercise. A poorly calibrated prescription risks either undertreating a patient capable of higher workloads or triggering ischemia/arrhythmia in a high-risk patient.

Checkpoint A: Pre-Draft Intake (Mandatory)

What is the qualifying diagnosis — post-MI, post-CABG, post-PCI, stable angina, HFrEF, post-valve surgery/intervention? (default: "Qualifying diagnosis not specified")
When was the index event or surgery? (default: "Date not provided")
What is the most recent LVEF? (default: "LVEF not documented")
Was a baseline exercise stress test performed with METs achieved? (default: "No baseline stress test available")
What is the patient's resting HR, BP, and current medications (especially beta-blockers)? (default: "Vitals and medications not provided")
Are there any exercise contraindications — unstable angina, decompensated HF, uncontrolled arrhythmia, severe AS, acute PE? (default: "No known contraindications")
What is the patient's current functional status — independent ADLs, ambulatory, or limited? (default: "Functional status not assessed")
Are there musculoskeletal or neurologic limitations affecting exercise? (default: "No known limitations")

Documents to Request

Discharge summary from index event
Exercise stress test results (METs, HR response, ECG findings)
Echocardiogram report (LVEF, valve function)
Current medication list with dosages
BNP/NT-proBNP if heart failure
Surgical/procedural report (CABG, PCI, valve)
Device interrogation if ICD/CRT present
Physical therapy or occupational therapy assessments if available
Patient's goals and preferences documentation

Step 1: Risk Stratification for Exercise

AHA/AACVPR Risk Stratification:

| Risk Level | Criteria | Monitoring Level | |-----------|---------|-----------------| | Low | Uncomplicated MI/PCI, LVEF ≥ 50%, no ischemia on stress test, no complex arrhythmia, functional capacity ≥ 7 METs | ECG monitoring initial sessions → discontinue when stable | | Moderate | LVEF 40–49%, or mild residual ischemia, or functional capacity 5–6.9 METs, or inability to self-monitor | Continuous ECG monitoring × 6–12 sessions | | High | LVEF < 40%, complex ventricular arrhythmia, exercise-induced ischemia at low workload (< 5 METs), hemodynamic instability | Continuous ECG monitoring throughout program, physician-supervised sessions |

Absolute Contraindications to Exercise:

Unstable angina (not yet stabilized)
Decompensated heart failure
Uncontrolled arrhythmia causing symptoms or hemodynamic compromise
Severe symptomatic aortic stenosis
Acute PE or pulmonary infarction
Acute myocarditis or pericarditis
Acute aortic dissection

Step 2: Exercise Prescription (FITT Principle)

Frequency: 3–5 sessions per week (minimum 36 sessions over 12–18 weeks per CMS coverage)

Intensity Prescription Methods:

| Method | Calculation | Best For | |--------|-----------|----------| | HR reserve (Karvonen) | THR = [(HRmax − HRrest) × %intensity] + HRrest | Most accurate; requires max HR from stress test | | % of HRmax | THR = HRmax × %intensity | When stress test available | | RPE (Borg 6–20 scale) | Target: 11–14 ("fairly light" to "somewhat hard") | When HR unreliable (AFib, paced rhythm, beta-blocker) | | METs method | Target: 40–80% of peak METs from stress test | When precise MET data available | | Talk test | Able to speak in sentences but not sing | Supplementary; useful for patient self-monitoring |

Starting Intensity (by risk level):

Low risk: 60–80% HR reserve or 12–14 RPE
Moderate risk: 50–70% HR reserve or 11–13 RPE
High risk: 40–60% HR reserve or 10–12 RPE; supervised

Time: 20–60 minutes of aerobic exercise per session (start at 15–20 for deconditioned patients, progress by 5 min/week)

Type:

Aerobic: treadmill walking, stationary cycling, arm ergometry, recumbent stepping
Resistance training: begin 2–3 weeks post-event for low/moderate risk; 5–6 weeks for high risk or post-sternotomy; 1–3 sets of 10–15 reps at 30–50% of 1-RM
Flexibility: gentle stretching, 5–10 minutes, every session

Step 3: Monitoring and Progression

Session Monitoring Checklist:

Pre-exercise: BP, HR, rhythm (ECG if monitored), symptoms, weight
During exercise: HR, RPE, rhythm, symptoms every 5–10 minutes
Post-exercise: BP, HR recovery, symptoms, 6-minute walk distance (periodic)
Abnormal responses requiring exercise modification or termination: SBP drop > 20 mmHg, chest pain, ST changes, new arrhythmia, HR > prescribed zone, SpO₂ < 88%

Progression Protocol:

Advance by one variable at a time (increase duration before intensity)
Increase duration by 5 minutes when tolerated × 2 consecutive sessions
Increase intensity by 5% HR reserve when current level tolerated for full sessions × 1 week
Transition from continuous to interval training when functional capacity improves to > 5 METs
Goal: 150 minutes/week moderate-intensity or 75 minutes/week vigorous by program completion

Step 4: Comprehensive Risk Factor Management

Core Components Beyond Exercise:

| Component | Target/Action | |-----------|--------------| | Blood pressure | < 130/80 mmHg; medication optimization | | Lipids | LDL < 70 mg/dL (< 55 if very high risk); high-intensity statin | | Diabetes | HbA1c < 7% (individualized); SGLT2i if HF | | Smoking | Absolute cessation; pharmacotherapy (varenicline, NRT, bupropion) | | Weight | BMI < 30 kg/m²; waist circumference targets | | Psychosocial | Screen for depression (PHQ-9), anxiety; refer for counseling | | Nutrition | Mediterranean or DASH diet; sodium < 2 g/day for HF; referral to dietitian |

Outcome Metrics to Track:

Functional capacity (METs improvement from baseline)
6-minute walk distance (improvement ≥ 30 m is clinically meaningful)
LVEF reassessment at program completion (HF patients)
Medication adherence rates
Risk factor targets achieved (% at goal)
Patient-reported outcomes (quality of life, depression scores)

Step 5: Program Completion and Transition

Phase Progression:

Phase I: Inpatient (mobilization post-event, education, discharge planning)
Phase II: Supervised outpatient (36 sessions per CMS; up to 72 with intensive cardiac rehab)
Phase III: Maintenance (community-based, self-monitored, lifelong)

Transition Plan for Phase III:

Document final exercise capacity (repeat stress test if indicated)
Provide written home exercise prescription with HR zones, RPE targets, and warning symptoms
Ensure all risk factor targets are addressed with ongoing medical management
Coordinate with PCP and cardiologist for long-term follow-up
Recommend community exercise program or gym-based maintenance
Establish patient self-monitoring protocol (HR, BP, symptoms, weight)

Checkpoint B: Post-Draft Alignment (Mandatory)

Is the risk stratification documented with justification for monitoring level?
Is the exercise prescription specific — frequency, intensity (HR or RPE), time, and type?
Are progression criteria defined?
Are all core components (nutrition, psychosocial, smoking, lipids) addressed?
Is the transition plan to maintenance documented?

Quality Audit

[ ] Qualifying diagnosis and eligibility confirmed
[ ] Risk stratification level assigned (low/moderate/high)
[ ] Baseline functional capacity documented (METs or 6MWD)
[ ] Exercise prescription follows FITT format with specific parameters
[ ] Intensity calculated using HR reserve, %MPHR, or RPE with method documented
[ ] Monitoring level matches risk stratification
[ ] Contraindications screened and documented
[ ] Resistance training initiation timing appropriate for diagnosis
[ ] Progression criteria defined (duration before intensity)
[ ] Risk factor targets documented for each core component
[ ] Depression screening performed (PHQ-9 or equivalent)
[ ] Smoking cessation addressed with pharmacotherapy if applicable
[ ] Phase III transition plan with home exercise prescription
[ ] Session attendance tracked against CMS 36-session benchmark

Guidelines

Every ACS, CABG, PCI, valve surgery, and HFrEF patient should receive an automatic cardiac rehab referral at discharge — referral gaps are the primary barrier to enrollment.
Exercise prescriptions must be individualized — a generic "walk 30 minutes" instruction is insufficient. Specify HR zone, RPE target, and progression plan.
Patients on beta-blockers have blunted HR response — use RPE as the primary intensity guide rather than relying solely on HR targets.
In HFrEF patients, monitor weight daily and hold exercise if weight gain > 2 kg in 48 hours (fluid overload) until diuretic adjustment.
Resistance training post-sternotomy requires 6–8 weeks of healing before upper-body exercises — start with lower-extremity resistance and progress.
Depression and anxiety screening at intake and periodically during the program is mandatory — untreated depression doubles cardiac event recurrence risk.
Document exercise-related adverse events (arrhythmia, angina, hypotension) and the clinical response — this data informs ongoing risk stratification.
CMS covers 36 sessions over 36 weeks; intensive cardiac rehab covers up to 72 sessions — document medical necessity if extended program is needed.